New Clinical Findings Suggest SUBLOCADE® Rapid Induction Boosts Opioid Treatment Retention Rates Recent clinical trial results highlight the efficacy of rapid SUBLOCADE® induction for improving retention rates in opioid use disorder treatment, particularly for high-risk patients.

New Clinical Findings Suggest SUBLOCADE® Rapid Induction Boosts Opioid Treatment Retention Rates #United_States #Richmond #SUBLOCADE #opioid_use_disorder #Indivior_PLC

Indivior Completes Cancellation of Secondary Listing on London Stock Exchange Indivior PLC has announced the successful cancellation of its secondary listing on the London Stock Exchange while maintaining its primary listing on Nasdaq. Learn more about this strategic move.

Indivior Completes Cancellation of Secondary Listing on London Stock Exchange #United_Kingdom #Richmond #Opioid_Treatment #Indivior_PLC #Nasdaq_Stock_Exchange

Indivior Appoints Patrick Barry as Chief Commercial Officer, Strengthening Leadership in Opioid Treatment Indivior PLC has appointed Patrick Barry as Chief Commercial Officer to enhance its growth strategy in treating opioid use disorder, effective June 2.

Indivior Appoints Patrick Barry as Chief Commercial Officer, Strengthening Leadership in Opioid Treatment #United_States #Richmond #Opioid_Treatment #Indivior_PLC #Patrick_Barry